Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
Ulmert, David LU ; O'Brien, M Frank ; Bjartell, Anders LU and Lilja, Hans LU
(2009)
In Nature Reviews Urology
6(7).
p.384-391
- Abstract
- The kallikrein, prostate-specific antigen (PSA), is one of the world's most frequently used disease biomarkers. After almost two decades of research and clinical experience, the diagnostic and monitoring limitations of PSA are beginning to be understood. Most physicians are aware of PSA's low specificity for cancer among older men with benign prostatic conditions; fewer are aware of recent data, which show that a prior negative biopsy or a prior PSA value below the threshold for biopsy might compromise the predictive accuracy of PSA even further. Furthermore, a subtle increase in serum PSA level during early middle age is strongly correlated with clinically important prostate cancer. We review current and past reports on the prostate... (More)
- The kallikrein, prostate-specific antigen (PSA), is one of the world's most frequently used disease biomarkers. After almost two decades of research and clinical experience, the diagnostic and monitoring limitations of PSA are beginning to be understood. Most physicians are aware of PSA's low specificity for cancer among older men with benign prostatic conditions; fewer are aware of recent data, which show that a prior negative biopsy or a prior PSA value below the threshold for biopsy might compromise the predictive accuracy of PSA even further. Furthermore, a subtle increase in serum PSA level during early middle age is strongly correlated with clinically important prostate cancer. We review current and past reports on the prostate kallikreins PSA and hK2 in relation to pathology and epidemiology. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1453393
- author
- Ulmert, David
LU
; O'Brien, M Frank
; Bjartell, Anders
LU
and Lilja, Hans
LU
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Nature Reviews Urology
- volume
- 6
- issue
- 7
- pages
- 384 - 391
- publisher
- Nature Publishing Group
- external identifiers
-
- wos:000267784600011
- pmid:19578355
- scopus:74949139859
- pmid:19578355
- ISSN
- 1759-4820
- DOI
- 10.1038/nrurol.2009.123
- language
- English
- LU publication?
- yes
- id
- 46ba6bc7-99e1-401b-b038-4448e8f09e28 (old id 1453393)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19578355?dopt=Abstract
- date added to LUP
- 2016-04-04 07:37:38
- date last changed
- 2022-03-15 07:09:01
@article{46ba6bc7-99e1-401b-b038-4448e8f09e28,
abstract = {{The kallikrein, prostate-specific antigen (PSA), is one of the world's most frequently used disease biomarkers. After almost two decades of research and clinical experience, the diagnostic and monitoring limitations of PSA are beginning to be understood. Most physicians are aware of PSA's low specificity for cancer among older men with benign prostatic conditions; fewer are aware of recent data, which show that a prior negative biopsy or a prior PSA value below the threshold for biopsy might compromise the predictive accuracy of PSA even further. Furthermore, a subtle increase in serum PSA level during early middle age is strongly correlated with clinically important prostate cancer. We review current and past reports on the prostate kallikreins PSA and hK2 in relation to pathology and epidemiology.}},
author = {{Ulmert, David and O'Brien, M Frank and Bjartell, Anders and Lilja, Hans}},
issn = {{1759-4820}},
language = {{eng}},
number = {{7}},
pages = {{384--391}},
publisher = {{Nature Publishing Group}},
series = {{Nature Reviews Urology}},
title = {{Prostate kallikrein markers in diagnosis, risk stratification and prognosis.}},
url = {{http://dx.doi.org/10.1038/nrurol.2009.123}},
doi = {{10.1038/nrurol.2009.123}},
volume = {{6}},
year = {{2009}},
}